Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Coultreon Biopharma Appoints Prista Charuworn As Chief Medical Officer

PRIVATEAug 18, 2026•about 4 hours ago

Position

Chief Medical Officer

Company

Coultreon Biopharma

Prista Charuworn
BiotechnologyHealth CareTherapeutics

Description

Coultreon Biopharma announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn brings extensive immunology drug development experience to accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671.

Company Information

Company

Coultreon Biopharma

About

Coultreon Biopharma, formerly known as Onco3R Therapeutics, is a biotechnology company based in Leuven, Belgium. The company develops therapies targeting clinically-validated pathways across immunology and metabolic diseases. With a focus on salt-inducible kinase (SIK) biology, Coultreon aims to deliver broader and more durable disease control through innovative drug discovery. Their lead program, COL-5671, is a highly selective SIK3 inhibitor currently in clinical development for autoimmune diseases.

Don't miss Coultreon Biopharma's next move

Get an email the moment Coultreon Biopharma changes its leadership, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Coultreon Biopharma's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.